A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms. Owen DH, Benner B, Wei L, Sukrithan V, et al. Clin Cancer Res 2023;29:731-741.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Owen DH, Benner B, Wei L, Sukrithan V, et al. A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms. Clin Cancer Res 2023;29:731-741.
PMID: 36255391